Extracellular Vesicles in Glioma: From Tumor Microenvironment Reprogramming to Liquid Biopsy and Therapeutic Translation

Gliomas remain refractory to contemporary neurosurgical and adjuvant therapies due to diffuse infiltration, immune evasion, and rapid development of therapeutic resistance. Extracellular vesicles (EVs), lipid-encapsulated substrates of various sizes that carry nucleic acid or proteins, are now recognized as central regulators of tumor–immune crosstalk and a potential unifying mechanism linking microenvironmental reprogramming with disease progression. Glioma-derived EVs function as active signaling platforms that remodel the tumor microenvironment. EV cargo—including PD-L1, TGF-β, and regulatory microRNAs—suppresses cytotoxic T-cell function, promotes M2 macrophage polarization, and impairs dendritic cell antigen presentation, collectively reinforcing an immunosuppressive niche. Additionally, EV-mediated transfer of resistance-associated cargo contributes to chemoresistance and radioresistance, representing key paracrine mechanisms of treatment failure. EV-associated nucleic acids specifically have enabled detection of alterations such as EGFRvIII, IDH1 mutations, and MGMT promoter methylation in early clinical studies. These findings support EV-based liquid biopsy as a promising approach for minimally invasive molecular characterization and disease monitoring. However, most mechanistic and therapeutic evidence remains preclinical, while clinical studies are limited by small cohorts, heterogeneous EV isolation and characterization methods, and a lack of prospective validation. Ultimately, EVs represent a biologically important interface between glioma biology and the immune microenvironment, with emerging applications in disease monitoring and therapeutic development. Prospective validation and technical standardization remain essential to enable clinical translation.

Authors

Institutions

Publication Details

Journal
Neuroglia
Published
2026-11-13
DOI
https://doi.org/10.3390/neuroglia7040044
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Extracellular Vesicles in Glioma: From Tumor Microenvironment Reprogramming to Liquid Biopsy and Therapeutic Translation

Michael J. Karsy, Nasser K. Yaghi, Hunter R. Underhill, Payam Ahmadi et al.
Neuroglia
Extracellular vesicles in disease
article

Extracellular Vesicles in Glioma: From Tumor Microenvironment Reprogramming to Liquid Biopsy and Therapeutic Translation

Michael J. Karsy, Nasser K. Yaghi, Hunter R. Underhill, Payam Ahmadi, Khushal A Gupta, Enes Demir, Carline Dugue
article en

Abstract

Gliomas remain refractory to contemporary neurosurgical and adjuvant therapies due to diffuse infiltration, immune evasion, and rapid development of therapeutic resistance. Extracellular vesicles (EVs), lipid-encapsulated substrates of various sizes that carry nucleic acid or proteins, are now recognized as central regulators of tumor–immune crosstalk and a potential unifying mechanism linking microenvironmental reprogramming with disease progression. Glioma-derived EVs function as active signaling platforms that remodel the tumor microenvironment. EV cargo—including PD-L1, TGF-β, and regulatory microRNAs—suppresses cytotoxic T-cell function, promotes M2 macrophage polarization, and impairs dendritic cell antigen presentation, collectively reinforcing an immunosuppressive niche. Additionally, EV-mediated transfer of resistance-associated cargo contributes to chemoresistance and radioresistance, representing key paracrine mechanisms of treatment failure. EV-associated nucleic acids specifically have enabled detection of alterations such as EGFRvIII, IDH1 mutations, and MGMT promoter methylation in early clinical studies. These findings support EV-based liquid biopsy as a promising approach for minimally invasive molecular characterization and disease monitoring. However, most mechanistic and therapeutic evidence remains preclinical, while clinical studies are limited by small cohorts, heterogeneous EV isolation and characterization methods, and a lack of prospective validation. Ultimately, EVs represent a biologically important interface between glioma biology and the immune microenvironment, with emerging applications in disease monitoring and therapeutic development. Prospective validation and technical standardization remain essential to enable clinical translation.

NeurogliaVol. 7(4)
Albert Einstein College of Medicine (US), Mashhad University of Medical Sciences (IR), Wayne State University (US), University of Utah (US), University of Michigan (US), Huntsman Cancer Institute (US)
National Cancer Institute
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon